search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


I CARE study; Improving Care After colon canceR treatment in the Netherlands. -Personalised care to Enhance quality of life-


- candidate number19591
- NTR NumberNTR4860
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR2-okt-2014
- Secondary IDsNL 51026.018.14 
- Public TitleI CARE study; Improving Care After colon canceR treatment in the Netherlands. -Personalised care to Enhance quality of life-
- Scientific TitleI CARE study; Improving Care After colon canceR treatment in the Netherlands. -Personalised care to Enhance quality of life-
- ACRONYMI CARE study
- hypothesisWe hypothesize that general practitioner (GP) involvement improves both aftercare and preventive care resulting in improved quality of life and patientsí satisfaction. Furthermore, a GP-led recurrence detection program leads to at least equal detection of recurrences. Also we hypothesize that the implementation of an e-health application (Oncokompas) to support patients in managing their own revalidation and aftercare and adapting to a healthier life leads to more attention for multi-morbidity, preventive care resulting in an improved quality of life and patientsí satisfaction. Finally, we hypothesize that GPs responsible for the recurrence detection programme will feel more responsible for aftercare which will enhance revalidation and quality of life.
- Healt Condition(s) or Problem(s) studiedColon cancer, Bowel cancer, Aftercare, E-health, Primary care
- Inclusion criteria- Carcinoma located in the colon and rectosigmoid defined as a tumour located 15 cm above the anal verge by coloscopy or above the sacral promontory as seen preoperatively
- Stage 1, 2 and 3 carcinoma
- Surgical treatment with curative intent
- Qualified for routine follow-up attendance by surgeon according to the national guideline.
- Patients with temporary stoma and who received adjuvant chemotherapy are also eligible.
- Exclusion criteria- Stage IV colorectal tumours
- Hereditary colorectal cancer
- Colorectal cancer in patients with inflammatory bowel disease
- Rectal cancer
- (Sub)total colectomy or proctocolectomy
- History of second primary cancer (except basal cell carcinoma of the skin) within the last 15 years
- Participation in other (clinical) research, which will affect the outcome measurements of this trial
- Permanent open wounds after surgery or other conditions where specialised care is needed
- Any other condition that warrants increased intensity of surveillance with respect to colon cancer follow-up
- Not able to speak Dutch or English
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupFactorial
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jan-2015
- planned closingdate31-dec-2021
- Target number of participants300
- Interventions1. Primary care-led follow-up and aftercare
2. Interactive personal website (Oncokompas)
- Primary outcomeQuality of life and patients' satisfaction
- Secondary outcomePhysical outcomes, psychosocial outcomes, number of investigations, referrals and related communication between secondary and primary care, (time) of recurrence detection, protocol adherence, attention to preventive care, cost effectiveness, and preference of care at the end of the trial
- Timepoints5 years
- Trial web site
- statusplanned
- CONTACT FOR PUBLIC QUERIESM.D. J. Wind
- CONTACT for SCIENTIFIC QUERIESM.D. J. Wind
- Sponsor/Initiator Academic Medical Center (AMC), Amsterdam
- Funding
(Source(s) of Monetary or Material Support)
KWF Kankerbestrijding, Stichting Alpe d'HuZes
- Publications-
- Brief summaryRationale
It is expected that in 2020 more than 17.000 patients with colorectal cancer will be diagnosed in the Netherlands. To date, after initial treatment patients are included in a surgeon-led programme with the main focus on recurrence detection. However, patients often experience multiple physical and psychosocial problems in this phase. Currently, in secondary care these problems are not always encountered and only a small number of distressed patients are identified and supported. Both the Dutch Health Council as the Dutch Cancer Foundation suggested more generalist care as a solution. Furthermore, for patients it would be preferable to be able to undergo rehabilitation as much as possible in their own environment. Evidence shows that web-based interventions for patient empowerment can improve care. An important development of these e-health facilities is the Oncokompas which is an e-health application which facilitates direct-to-user delivery of individualised healthcare.

Objective and hypothesis
The above mentioned developments are subject to the I CARE study. We hypothesize that general practitioner (GP) involvement improves both aftercare and preventive care resulting in improved quality of life and patientsí satisfaction. Furthermore, a GP-led recurrence detection programme leads to at least equal detection of recurrences. Also we hypothesize that the implementation of an e-health application (Oncokompas) to support patients in managing their own revalidation and aftercare and adapting to a healthier life leads to more attention for multi-morbidity, preventive care resulting in an improved quality of life and patientsí satisfaction. Finally, we hypothesize that GPs responsible for the recurrence detection programme will feel more responsible for aftercare which will enhance revalidation and quality of life.

Study design
The present study proposal consists of a multi-centre 2x2 factorial randomised controlled trial with a calculated total sample size of 300 patients, based on the EORTC QLQ-C30. Patients will be randomised in four groups; 1. usual follow-up visits and aftercare provided in secondary care (surgeon-led), 2. usual follow-up visits and aftercare provided in secondary care with additional use of the e-health application Oncokompas, 3. follow-up and aftercare in primary care (GP-led), and 4. follow-up and aftercare in primary care with additional use of the e-health application Oncokompas.

Study population
Patients with stage I, II, and III carcinoma located in the colon and rectosigmoid are eligible. Patients with temporary stoma and who receive adjuvant chemotherapy are also eligible.

Main study parameters/endpoints
Primary outcomes include quality of life and patient satisfaction. Secondary outcomes include physical outcomes, psychosocial outcomes, number of investigations, referrals and related communication between secondary and primary care, (time of) recurrence detection and protocol adherence, attention to preventive care, cost effectiveness, and preference of care at the end of the trial.
- Main changes (audit trail)
- RECORD2-okt-2014 - 21-dec-2014


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl